Pulmonology/Pneumology is a specialty of the branch of internal medicine that is linked with the diseases/disorders of lungs and the respiratory tract. This specialty (area of expertise) of medicine is even well known as chest medicine/respiratory medicine in many parts of the world! Doctors that practice pulmonology are termed as pulmonologists, skilled in diagnosis and medical treatment of lung diseases/disorders!
MedicExchange through this section has comprehensive data about a variety of hi-tech pulmonary systems from world-class pulmonary system suppliers that offer advanced quality pulmonary system brands to healthcare/medical professionals (Pulmonology specialists/Pulmonary specialist etc.) over the globe, and you can experience best of Pulmonology solutions, and supported Pulmonology services from these pulmonary system companies, browsing through us, in a zap!
Do not delay and make the most of advanced quality pulmonary equipments, various other mechanized/reliable pulmonology products for effective diagnosis and management of a variety of lung conditions!
Browse extensively through us for coming across oodles of Pulmonology Imaging Products, and gain from a variety of Pulmonology Solutions and Services, hi-tech Pulmonology Equipments, Pulmonary EMR Software, and Pulmonary Medical Transcription Companies etc.!
Other than profiting from a variety of Pulmonology products, Pulmonology services, and innovative Pulmonology solutions from world-class companies/vendors of pulmonary systems/products, you can even stop over for some Healthcare News, Healthcare Blogs, Whitepapers, and Webinars, through us for to stay updated on the Healthcare sector!
- Product Types: Lung CAD | Pulmonary Diagnostic and Therapeutic Accessories | Pulmonary EMR Software | Pulmonary Medical Transcription Services
ACR Statement on CT Lung Cancer Screening Cost Effectiveness: Standards and Infrastructure Needed to Support Widespread Screening
The American College of Radiology (ACR) is pleased that initial data from the National Lung Cancer Screening Trial (NLST) cost effectiveness analysis, presented at the Joint Meeting of the National Institutes of Health Board of Scientific Advisors and National Cancer Advisory Board, suggests that computed tomography (CT) lung cancer screening for high-risk patients (those ages 55-74, 30 pack years of smoking) is cost effective. The College looks forward to publication of NLST cost effectiveness analysis results. The ACR will use that information in the ongoing creation of guidelines and standards for these exams and to address staffing and care models needed to support widespread screening.
Data from two studies proves that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) greatly reduces lung tissue loss in patients with emphysema related to AAT deficiency.
Combined use of market-leading diagnostic technologies opens door to treatment options
Covidien (NYSE: COV), a leading global provider of healthcare products, announced an agreement with VIDA Diagnostics, a pioneer in quantitative pulmonary imaging analysis software. Under the agreement, Covidien will distribute VIDA’s Apollo® pulmonary imaging software services.
Covidien’s Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest Physicians
Minimally invasive procedure aids early detection and diagnosis of lung cancer, potentially increasing long-term survival rates significantly.
Covidien (NYSE: COV), a leading global provider of healthcare products, announced that its superDimension Electromagnetic Navigation Bronchoscopy (ENB™) system, the first technology of its kind, is included in the new American College of Chest Physicians (ACCP) guidelines to aid in diagnosing and managing lung cancer. The evidence-based clinical practice guidelines were released by the ACCP earlier this month.
The diabetes drug metformin slows the growth of lung cancer cells and makes them more likely to be killed by radiotherapy, according to a study1 published in the British Journal of Cancer.
Scientists from McMaster University in Canada found that metformin acted on the defence mechanisms that non-small cell lung cancers — the most common form of the disease — use to resist radiotherapy.
Detection rate comparable to CT screening at a lower cost
Most lung cancers are detected when patients become symptomatic and have late-stage disease. However, recently, computed tomography (CT) screening for lung cancer has been reported to reduce lung cancer mortality. Since the National Lung Screening Trial's results showed a 20 percent reduction in lung cancer-specific deaths in those patients who had screening performed with chest CT, the use of CT screening for lung cancer has been gaining favor. However, CT is associated with the disadvantages of high radiation dosage and cost.
Exposure to tobacco smoke may predispose girls to developing chronic obstructive pulmonary disease (COPD) as adults, a Norwegian study showed.
Cancer Research UK scientists are the first to use an efficient new screening strategy to identify gene faults in tumour cells that are possible drug targets for the most common form of lung cancer, according to new research published in PNAS.
Cryoablation: Interventional radiologists present results of research on a new minimally invasive treatment option for advanced cancers that have spread to lung tissue
- Minimally invasive cryoablation freezes and kills cancerous tumors that have spread to the lung, suggests first results of the ECLIPSE trial.
- Cryoablation was 100 percent effective after three months, researchers found.
- While not a cure, cryoablation appears to extend patient survival.
- Interventional radiologists are doctors who specialize in minimally invasive targeted treatments. They use X-rays, MRI or other imaging to guide a catheter inside the body, usually in an artery, to treat at the source of disease.
A U.S. medical panel for the first time endorsed annual CT scans to detect lung cancer in current and former smokers, an effort to tackle the nation's biggest cancer killer that contrasted with a new caution from a separate medical group about overdiagnosis and overtreatment of cancer.
The U.S. Preventive Services Task Force, whose recommendations determine which therapies and tests must be provided by insurers under the Obama administration's new health law, concluded that about 20% of lung-cancer deaths might be avoided through early detection and treatment.
Study shows metabolite biomarker could improve spiral CT screening, help detect disease early.
Elevated levels of bilirubin in the blood get attention in the clinic because they often indicate that something has gone wrong with the liver. Now researchers have found that male smokers with low levels of the yellow-tinged chemical are at higher risk for lung cancer and dying from the disease.
Lung Cancer Alliance Applauds New NCI Study Showing Lung Cancer Screening As Cost Effective As Other Common Health Screenings
Adds To Growing Body of Evidence Supporting Integration of Lung Cancer Screening into Public Health
Lung Cancer Alliance (LCA) applauded a long awaited cost-benefit analysis, presented at a meeting of the National Cancer Institute's Board of Scientific Advisors and National Cancer Advisory Board, which concluded that a CT lung cancer screening program based on NCI's lung cancer screening trial meets generally accepted criteria for cost-effectiveness of a screening test.
Lung Cancer Alliance Congratulates American College of Chest Physicians for Reaffirming Benefit of Lung Cancer Screening for Those at High Risk
Commends growing number of medical centers adopting responsible screening practices laid out in the National Framework
Lung Cancer Alliance (LCA) congratulated the American College of Chest Physicians (ACCP) for reaffirming its support for lung cancer screening for those at risk. This is in response to ACCP's publishing of a special supplement to its May issue of CHEST, ACCP's peer-reviewed journal, which cites evidence that CT screening, through a structured protocol, can reduce lung cancer deaths among high risk individuals.
Lung Cancer Alliance Says Shame On Consumer Reports For Its Inaccurate Reporting On Lung Cancer Screening
Still Awaiting Correction After 4 Months of Repeated Requests to Revise its February Report on CT Screening of Those at Risk for Lung Cancer.
After four months of repeated requests to have Consumer Reports correct their inaccurate article on lung cancer screening, Lung Cancer Alliance (LCA) issued public criticism and released its original February 2013 letter to Consumer Reports' President & CEO James A. Guest. The LCA letter points out factual errors in the February article and highlights other shortcomings in its reporting of the scientifically proven benefit of CT screening for those at risk for lung cancer— now estimated to saves thousands of lives a year.
Lung cancer screening using computed tomography ( CT ) scans can be effective in high risk populations if it follows a strict clinical protocol supported by a multidisciplinary care team, said University of Cincinnati researchers this week.
Using low-dose CT scans to screen high-risk patients for lung tumors is far more effective at preventing lung cancer deaths than scanning those at low risk, according to a new analysis of over 53,000 volunteers.
The study, published in the New England Journal of Medicine, comes at a time when doctors are struggling to reduce the death rate among lung cancer patients, who account for more than one quarter of all cancer deaths.
Screening for lung cancer is now available and widely recommended for its potential to save the lives of potential patients, Time reported.
Lung cancer is the leading cause of cancer-related deaths in the U.S. this year and appears most often in patients who admit to regularly smoking. New studies suggest preliminary CT scans in smokers between the ages of 55 and 80 could reveal potential tumors.
Greater sensitivity, with lower radiation dose, allows for faster treatment, reported at 93rd AATS Annual Meeting
Lung cancer is associated with very high mortality, in part because it is hard to detect at early stages, but also because it can recur frequently after surgical removal. The question arises as to what is the best way to follow lung cancer patients after surgery in order to spot problems early enough, before symptoms become obvious, so that patients may still be eligible for new interventions. In this study presented at the 93rd AATS Annual Meeting, investigators from the University of Toronto departments of Thoracic Surgery and Diagnostic Radiology show that minimal dose computed tomography (MnDCT) of the thorax offers much greater sensitivity at detecting new or recurrent lung cancer, with equivalent amount of radiation, compared to conventional chest x-rays.
Minimal Dose Computed Tomography Scan of the Chest (MnDCT) delivers a radiation dose comparable to that of chest X-ray (CXR), with greater sensitivity for detecting new or recurrent lung cancer, according to a study presented at the annual meeting of the American Association for Thoracic Surgery, held from May 4–8 in Minneapolis.
More research is suggesting that heavy smokers may benefit from screening for lung cancer, to detect tumors in their earliest stages.
In a survey of patients with terminal lung cancer, nearly two-thirds did not understand that radiation treatments intended only to ease their symptoms would not cure their disease.
Among the nationwide sample of patients with advanced lung cancers, four out of five thought the radiation would help them live longer and two in five believed it might cure their cancers.
High-risk smokers can breathe a sigh of relief with a program at Northwest Community Healthcare (NCH) that diagnoses lung problems at the earliest possible stage.
For smokers and former smokers, the risk of getting lung cancer is much higher than for non-smokers. But high-risk smokers can breathe a sigh of relief with a program at Northwest Community Healthcare (NCH) that diagnoses lung problems at the earliest possible stage.
A multidisciplinary team of researchers at Mayo Clinic has developed a new software tool to noninvasively characterize pulmonary adenocarcinoma, a common type of cancerous nodule in the lungs. Results from a pilot study of the computer-aided nodule assessment and risk yield (CANARY) are published in the Journal of Thoracic Oncology.
Fewer clots are missed but many patients are harmed by unnecessary care, warn experts
The introduction of CT pulmonary angiography has been associated with an 80% rise in the detection of pulmonary emboli in the US, but with little change in death rates.
Professor Renda Soylemez Wiener and colleagues argue this is evidence of overdiagnosis. They say some patients are helped, but many are harmed by the adverse effects of unnecessary treatment.
New data from two clinical trials presented today at the International Liver Congress™ 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine tests.
HCC is common throughout the world and most often develops as a late complication of chronic viral hepatitis or cirrhosis of any cause. The overall survival rate of HCC is poor and so screening for HCC offers the best hope for early detection, eligibility for treatment, and improved survival. While effective therapies exist, the available screening tests to detect HCC – alpha-fetoprotein (AFP) and ultrasound – are reported to have low sensitivity and specificity (50–85% and 70–90%, respectively).
Researchers find improved overall survival for LS-SCLC patients
Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease, meaning the cancer is only present in one lung, but may have spread to lymph nodes or tissue between the lungs. These patients are often treated with chemotherapy and definitive radiation therapy. Staging information is essential because of the high propensity for metastatic disease in SCLC, and the identification of metastases can spare patients from the toxicity associated with thoracic radiotherapy. Furthermore, in those patients who do receive radiotherapy, knowing the exact extent of disease may permit more accurate treatment volume delineation.
Benign disease diagnosis rates after surgery for suspected lung cancer varied widely by state, and the reasons for these variations could inform health policy and clinical guidelines for lung cancer screening, according to a researcher who presented the data at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.
A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibrosis can be used to identify individuals at risk for this deadly lung disease.
Screening for lung cancer with low-dose computed tomography (LDCT) in all screening-eligible current and former smokers has the potential to avert approximately 12,000 lung cancer deaths each year in the United States. That is the conclusion of a new analysis published early online in CANCER, a peer-reviewed journal of the American Cancer Society. By providing a national estimate of potentially avertable lung cancer deaths, the study will help policy makers better understand the possible benefits of LDCT lung cancer screening.
As a leading manufacturer of CT technology, Siemens Healthcare supports the final evidence report and draft recommendation statement (www.uspreventiveservicestaskforce.org/newsroom.htm) issued by the U.S. Preventive Services Task Force (USPSTF) regarding CT screening for lung cancer.
A more restrictive definition of a positive result in CT screening for lung cancer could reduce the rate of false-positives and unnecessary follow-up tests, researchers reported.
But a higher threshold for baseline screening would have resulted in delayed diagnosis of as much as 9 months in about 6% of lung cancer patients, according to Claudia Henschke, MD, PhD, of Mount Sinai School of Medicine in New York City, and colleagues.
The U.S. Preventive Services Task Force (Task Force) posted its final evidence report and draft recommendation statement on screening for lung cancer. The Task Force is providing an opportunity for public comment on this draft recommendation statement until August 26. All public comments will be considered as the Task Force develops its final recommendation.
Based on the available evidence, the Task Force recommends screening people who are at high risk for lung cancer with annual low-dose CT scans, which can prevent a substantial number of lung cancerrelated deaths. This is a grade B draft recommendation. Smoking is the biggest risk factor for developing lung cancer, resulting in about 85 percent of lung cancers in the United States. The risk for developing lung cancer also increases with age, with most lung cancers occurring in people age 55 or older.
Updated results from a study published last year show that patients with massive pulmonary embolism (PE) treated with ultrasound-accelerated catheter-directed thrombolysis continue to show benefit 1 year later.
Complete Medical Services, A Leading Provider of Diagnostic Imaging Equipment
Hobbs Medical is a leading manufacturer and global supplier of accessories for flexible GI and Pulmonary Endoscopy.
Comprehensive, affordable and easy to adapt EHR solutions.